156 related articles for article (PubMed ID: 22509338)
1. Computational modeling-based discovery of novel classes of anti-inflammatory drugs that target lanthionine synthetase C-like protein 2.
Lu P; Hontecillas R; Horne WT; Carbo A; Viladomiu M; Pedragosa M; Bevan DR; Lewis SN; Bassaganya-Riera J
PLoS One; 2012; 7(4):e34643. PubMed ID: 22509338
[TBL] [Abstract][Full Text] [Related]
2. Molecular modeling of lanthionine synthetase component C-like protein 2: a potential target for the discovery of novel type 2 diabetes prophylactics and therapeutics.
Lu P; Bevan DR; Lewis SN; Hontecillas R; Bassaganya-Riera J
J Mol Model; 2011 Mar; 17(3):543-53. PubMed ID: 20512604
[TBL] [Abstract][Full Text] [Related]
3. Lanthionine synthetase component C-like protein 2: a new drug target for inflammatory diseases and diabetes.
Lu P; Hontecillas R; Philipson CW; Bassaganya-Riera J
Curr Drug Targets; 2014 Jun; 15(6):565-72. PubMed ID: 24628287
[TBL] [Abstract][Full Text] [Related]
4. An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease.
Carbo A; Gandour RD; Hontecillas R; Philipson N; Uren A; Bassaganya-Riera J
J Med Chem; 2016 Nov; 59(22):10113-10126. PubMed ID: 27933891
[TBL] [Abstract][Full Text] [Related]
5. Abscisic acid regulates inflammation via ligand-binding domain-independent activation of peroxisome proliferator-activated receptor gamma.
Bassaganya-Riera J; Guri AJ; Lu P; Climent M; Carbo A; Sobral BW; Horne WT; Lewis SN; Bevan DR; Hontecillas R
J Biol Chem; 2011 Jan; 286(4):2504-16. PubMed ID: 21088297
[TBL] [Abstract][Full Text] [Related]
6. Lanthionine synthetase C-like protein 2 (LanCL2) is important for adipogenic differentiation.
Dutta D; Lai KY; Reyes-Ordoñez A; Chen J; van der Donk WA
J Lipid Res; 2018 Aug; 59(8):1433-1445. PubMed ID: 29880530
[TBL] [Abstract][Full Text] [Related]
7. Modeling the Role of Lanthionine Synthetase C-Like 2 (LANCL2) in the Modulation of Immune Responses to Helicobacter pylori Infection.
Leber A; Bassaganya-Riera J; Tubau-Juni N; Zoccoli-Rodriguez V; Viladomiu M; Abedi V; Lu P; Hontecillas R
PLoS One; 2016; 11(12):e0167440. PubMed ID: 27936058
[TBL] [Abstract][Full Text] [Related]
8. Identification of a high affinity binding site for abscisic acid on human lanthionine synthetase component C-like protein 2.
Cichero E; Fresia C; Guida L; Booz V; Millo E; Scotti C; Iamele L; de Jonge H; Galante D; De Flora A; Sturla L; Vigliarolo T; Zocchi E; Fossa P
Int J Biochem Cell Biol; 2018 Apr; 97():52-61. PubMed ID: 29421190
[TBL] [Abstract][Full Text] [Related]
9. LANCL2 is necessary for abscisic acid binding and signaling in human granulocytes and in rat insulinoma cells.
Sturla L; Fresia C; Guida L; Bruzzone S; Scarfì S; Usai C; Fruscione F; Magnone M; Millo E; Basile G; Grozio A; Jacchetti E; Allegretti M; De Flora A; Zocchi E
J Biol Chem; 2009 Oct; 284(41):28045-28057. PubMed ID: 19667068
[TBL] [Abstract][Full Text] [Related]
10. Activation of LANCL2 by BT-11 Ameliorates IBD by Supporting Regulatory T Cell Stability Through Immunometabolic Mechanisms.
Leber A; Hontecillas R; Zoccoli-Rodriguez V; Bassaganya-Riera J
Inflamm Bowel Dis; 2018 Aug; 24(9):1978-1991. PubMed ID: 29718324
[TBL] [Abstract][Full Text] [Related]
11. Abscisic acid signaling through LANCL2 and PPARγ induces activation of p38MAPK resulting in dormancy of prostate cancer metastatic cells.
Parajuli KR; Jung Y; Taichman RS
Oncol Rep; 2024 Mar; 51(3):. PubMed ID: 38624012
[TBL] [Abstract][Full Text] [Related]
12. Expression of PPAR γ in intestinal epithelial cells is dispensable for the prevention of colitis by dietary abscisic acid.
Hontecillas R; Bassaganya-Riera J
ESPEN J; 2012 Oct; 7(5):e189-e195. PubMed ID: 23814701
[TBL] [Abstract][Full Text] [Related]
13. Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease.
Hontecillas R; Horne WT; Climent M; Guri AJ; Evans C; Zhang Y; Sobral BW; Bassaganya-Riera J
Mucosal Immunol; 2011 May; 4(3):304-13. PubMed ID: 21068720
[TBL] [Abstract][Full Text] [Related]
14. Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn's Disease.
Tubau-Juni N; Hontecillas R; Leber AJ; Alva SS; Bassaganya-Riera J
Inflamm Bowel Dis; 2024 Apr; 30(4):671-680. PubMed ID: 37934790
[TBL] [Abstract][Full Text] [Related]
15. Lanthionine Synthetase C-Like 2 Modulates Immune Responses to Influenza Virus Infection.
Leber A; Bassaganya-Riera J; Tubau-Juni N; Zoccoli-Rodriguez V; Lu P; Godfrey V; Kale S; Hontecillas R
Front Immunol; 2017; 8():178. PubMed ID: 28270815
[TBL] [Abstract][Full Text] [Related]
16. New Insights into the LANCL2-
Scarano N; Di Palma F; Origlia N; Musumeci F; Schenone S; Spinelli S; Passalacqua M; Zocchi E; Sturla L; Cichero E; Cavalli A
Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140095
[TBL] [Abstract][Full Text] [Related]
17. First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis.
Tubau-Juni N; Hontecillas R; Leber A; Maturavongsadit P; Chauhan J; Bassaganya-Riera J
Sci Rep; 2021 Oct; 11(1):19827. PubMed ID: 34615968
[TBL] [Abstract][Full Text] [Related]
18. Binding of abscisic acid to human LANCL2.
Sturla L; Fresia C; Guida L; Grozio A; Vigliarolo T; Mannino E; Millo E; Bagnasco L; Bruzzone S; De Flora A; Zocchi E
Biochem Biophys Res Commun; 2011 Nov; 415(2):390-5. PubMed ID: 22037458
[TBL] [Abstract][Full Text] [Related]
19. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
[TBL] [Abstract][Full Text] [Related]
20. T cell PPARγ is required for the anti-inflammatory efficacy of abscisic acid against experimental IBD.
Guri AJ; Evans NP; Hontecillas R; Bassaganya-Riera J
J Nutr Biochem; 2011 Sep; 22(9):812-9. PubMed ID: 21109419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
